Condensed

See the latest coronavirus and vaccine informationLearn about the Lancaster General Hospital Emergency Department expansion and related traffic changes.

A clinical trial looking at the impact of supplements on patients with COVID-19 is now underway at the Research Institute at Penn Medicine Lancaster General Health and is enrolling participants. This is just the latest of several research studies aimed at discovering optimal treatments for the coronavirus infection in our community and beyond.

COVID-19 Supplement Study

Corey Fogelman, MD, and other investigators from our Department of Family and Community Medicine, are leading a double-blind study to determine whether symptomatic and asymptomatic COVID-19 patients can benefit from taking vitamin C or melatonin during the course of their illness. The study team will send a daily survey for 14 days to participants to share their symptoms.

Patients 40 years or older with COVID-19 who are interested in learning more about clinical research using low-risk vitamins and supplements may call (717) 719-3116 or fill out a screening form.

COVID-19 Convalescent Plasma Expanded Access Program

Since April, patients at Lancaster General Hospital received convalescent plasma as a therapy for COVID-19. Our Research Institute and lead investigator Joseph Kontra, MD, Chief of Infectious Disease, helped build a body of knowledge about this therapy through participation in Mayo Clinic’s COVID-19 Convalescent Plasma Expanded Access program. This program led to Emergency Use Authorization which allows health-care providers to treat suspected or laboratory-confirmed COVID-19 in hospitalized patients. People who have recovered from COVID-19 can donate plasma at Lancaster General Hospital.

ECMOCARD

The ECMOCARD study, led locally by Dr. Mark Epler, LG Health Physicians Cardiothoracic Surgery, is collecting data on disease progression in COVID-19 patients who require mechanical ventilation.

DARE-19

Eric McCamant, MD, is leading the DARE-19 study locally to evaluate the effect of dapagliflozin, a drug used to treat diabetes, in reducing disease progression and complications in patients who are hospitalized with COVID-19. This international study is offering hospitals better ways to reduce respiratory problems in patients requiring mechanical ventilation.

Surveillance of COVID-19 in a Single Institution

Adam Lake, MD, is the principal investigator in a study of patients who are seeking care for an upper or lower respiratory infection or flu-like symptoms, or are asking to be tested for COVID-19. This study will look at the link between patient data and who is tested, who has COVID-19, and outcomes of the disease. It is a series of 3 surveys: a first survey now, a second at 90 days and a third at 180 days. Patients who meet the criteria are invited to join the study.

 
Share This Page: